We focus on the industry's transition away from Poly-L-lactic acid-type resorbable polymers to updated and novel resorbable biomaterials designed for better clinical performance.
ROSA's first five cases were performed in a single surgery day by one surgeon. This perhaps hints that the company will position of ROSA as efficient and minimally disruptive to procedure flow.
How will companies prioritize future R&D initiatives? We expect they'll balance development of smart implants, customization, materials, less-invasive surgery, tissue engineering and regrowth with requirements of data/evidence-based medicine and regulatory changes.
Paradigm Spine specializes in motion preservation and non-fusion spinal devices. The cash and stock transaction, valued at US $300MM, is slated to close in 1Q19.
Investors at the Musculoskeletal New Ventures Conference pointed to extremities, sports medicine, digital health and hospital supply chain as areas attractive for innovation, funding and M&A.
Manufacturers need not rely on go/no-go gaging methods. With non-contact video and multi-sensor systems, not only can 100% inspection be realized, but speed and throughput can increase.
Our global industry requires companies to develop harmonized postmarket surveillance systems that minimize inconsistencies in our understanding of product lifecycle risks.
